AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23714235 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic calcium phosphate with autogenous bone (BCPAB)
Number of subjects: 8
Study 23221616 — intervention group
Group type: EXPERIMENTAL
Intervention: Adventure-based training programme
Number of subjects: 120
Study 23221616 — intervention group
Group type: COMPARATOR
Intervention: Attention placebo control group
Number of subjects: 120
Study 21437932 — intervention group
Group type: EXPERIMENTAL
Intervention: Good collateral flow
Number of subjects: 287
Study 18799887 — intervention group
Group type: EXPERIMENTAL
Intervention: Betadine vaginal preparation (not washed out)
Number of subjects: 721
Study 18799887 — intervention group
Group type: COMPARATOR
Intervention: Control group (betadine cleansed by saline irrigation)
Number of subjects: 721
Study 16171712 — intervention group
Group type: EXPERIMENTAL
Intervention: Myocardial perfusion imaging (MPI) using a gated dual-isotope protocol
Number of subjects: 357
Study 16171712 — intervention group
Group type: COMPARATOR
Intervention: Angiography (reference standard)
Number of subjects: 357
Study 12849673 — intervention group
Group type: EXPERIMENTAL
Intervention: Picotamide (a renal TxA(2) synthase and TxA(2)/prostaglandin H(2) receptor inhibitor)
Number of subjects: 14
Study 12849673 — intervention group
Group type: EXPERIMENTAL
Intervention: Picotamide
Number of subjects: 14
Study 10458353 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical prostaglandin E1 gel plus 5% SEPA
Number of subjects: 48
Study 10458353 — intervention group
Group type: COMPARATOR
Intervention: SEPA alone (placebo)
Number of subjects: 48
Study 8911260 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive broad-spectrum empirical antimicrobial therapy (imipenem and cilastatin sodium, 500 mg, intravenously, every 6 hours)
Number of subjects: 213
Study 8911260 — intervention group
Group type: COMPARATOR
Intervention: Limited-spectrum empirical antimicrobial therapy (cefoxitin sodium, 2 g, intravenously, every 6 hours)
Number of subjects: 213
Study 1875313 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuth Iodoform Paraffin Paste (BIPP) socket dressing
Number of subjects: 148
Study 1875313 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary closure using a resorbable suture (Softgut)
Number of subjects: 148
Study 1875313 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic metronidazole
Number of subjects: 148
Study 7131550 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient package insert (PPI)
Number of subjects: 249
Study 7131550 — intervention group
Group type: COMPARATOR
Intervention: No patient package insert (non-PPI)
Number of subjects: 249
Study 31050933 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode Laser (DL) as an adjunct to Kirkland flap surgery
Number of subjects: 20
Study 28314755 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol dose escalation for 12 months; increased monthly until SU <6 mg/dL.
Number of subjects: 183
Study 28314755 — intervention group
Group type: COMPARATOR
Intervention: Control group continuing current dose of allopurinol.
Number of subjects: 183
Study 28314755 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol dose escalation group.
Number of subjects: 183
Study 28314755 — intervention group
Group type: COMPARATOR
Intervention: Control group.
Number of subjects: 183
Study 28314755 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups.
Number of subjects: 183
Study 26669202 — intervention group
Group type: EXPERIMENTAL
Intervention: Santong needling
Number of subjects: 60
Study 26669202 — intervention group
Group type: COMPARATOR
Intervention: Control group (Jingjin puncture)
Number of subjects: 60
Study 24456367 — intervention group
Group type: EXPERIMENTAL
Intervention: Korean traditional diet (KTD)
Number of subjects: 41
Study 24456367 — intervention group
Group type: COMPARATOR
Intervention: Control group (eat as usual)
Number of subjects: 41
Study 22232085 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (300-450 mg/day)
Number of subjects: 119
Study 22232085 — intervention group
Group type: COMPARATOR
Intervention: Pregabalin
Number of subjects: 119
Study 22232085 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study 19916994 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized dosing of enoxaparin
Number of subjects: 118
Study 19916994 — intervention group
Group type: COMPARATOR
Intervention: Conventional dosing of enoxaparin
Number of subjects: 118
Study 17290026 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant activated factor VII (rFVIIa)
Number of subjects: 0
Study 17290026 — intervention group
Group type: COMPARATOR
Intervention: Control not specified
Number of subjects: 0
Study 17290026 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 0
Study 15065473 — intervention group
Group type: COMPARATOR
Intervention: Decisional Control group
Number of subjects: 102
Study 15065473 — intervention group
Group type: COMPARATOR
Intervention: No‐Decisional Control group
Number of subjects: 102
Study 15065473 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual Control group
Number of subjects: 102
Study 15065473 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal appraisals (Impact Message Inventory)
Number of subjects: 102
Study 15065473 — intervention group
Group type: EXPERIMENTAL
Intervention: Oppressive interpersonal impacts (physician low friendliness, patient low friendliness, high dominance, high hostility)
Number of subjects: 102
Study 11320542 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAID administered 3 doses during 24 hours before surgery
Number of subjects: 60
Study 11320542 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered
Number of subjects: 60
Study 9205582 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprascapular nerve block
Number of subjects: 20
Study 9205582 — intervention group
Group type: COMPARATOR
Intervention: Intra-articular local anaesthetic
Number of subjects: 20
Study 7907668 — intervention group
Group type: EXPERIMENTAL
Intervention: Deliberate increase of oxygen delivery index to greater than 600 mL/min per square meter using dopexamine hydrochloride infusion
Number of subjects: 107
Study 7907668 — intervention group
Group type: COMPARATOR
Intervention: Best standard perioperative care
Number of subjects: 107
Study 2877912 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine 40 mg h.s.
Number of subjects: 384
Study 2877912 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine 40 mg b.i.d.
Number of subjects: 384
Study 2877912 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine 20 mg b.i.d.
Number of subjects: 384
Study 2877912 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 384
Study 29522362 — intervention group
Group type: EXPERIMENTAL
Intervention: ADT+D (androgen deprivation therapy with docetaxel)
Number of subjects: 790
Study 29522362 — intervention group
Group type: COMPARATOR
Intervention: ADT (androgen deprivation therapy alone)
Number of subjects: 790
Study 29522362 — intervention group
Group type: EXPERIMENTAL
Intervention: ADT+D
Number of subjects: 790
Study 29522362 — intervention group
Group type: COMPARATOR
Intervention: ADT
Number of subjects: 790
Study 27509064 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental automation-assisted approach
Number of subjects: 20
Study 27509064 — intervention group
Group type: COMPARATOR
Intervention: Standard protocols and equipment (Control)
Number of subjects: 20
Study 27509064 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 20
Study 25327918 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjunctival auto-graft (n=26)
Number of subjects: 57
Study 25327918 — intervention group
Group type: COMPARATOR
Intervention: Conjunctival rotation flap (n=31)
Number of subjects: 57
Study 25327918 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjunctival auto-graft and Conjunctival rotation flap
Number of subjects: 57
Study 23491524 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 mg ticagrelor twice daily
Number of subjects: 30
Study 23491524 — intervention group
Group type: COMPARATOR
Intervention: 10 mg prasugrel once daily
Number of subjects: 30
Study 20973462 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality Protein Maize (QPM)
Number of subjects: 362
Study 20973462 — intervention group
Group type: COMPARATOR
Intervention: Conventional maize
Number of subjects: 362
Study 18494750 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART
Number of subjects: 0
Study 16707975 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatic sphincterotomy
Number of subjects: 11
Study 16707975 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual sphincterotomy
Number of subjects: 11
Study 16707975 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic pancreatic stenting
Number of subjects: 11
Study 12502975 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% oxygen
Number of subjects: 36
Study 12502975 — intervention group
Group type: EXPERIMENTAL
Intervention: 80% oxygen
Number of subjects: 36
Study 12502975 — intervention group
Group type: EXPERIMENTAL
Intervention: 60% oxygen
Number of subjects: 36
Study 10755205 — intervention group
Group type: EXPERIMENTAL
Intervention: Rescue thrombolysis with rTPA 50 mg (10 mg bolus + 40 mg in 60 minutes)
Number of subjects: 90
Study 10755205 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 10755205 — intervention group
Group type: EXPERIMENTAL
Intervention: Rescue thrombolysis with rTPA
Number of subjects: 90
Study 9103739 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent training treatment group (PT)
Number of subjects: 97
Study 9103739 — intervention group
Group type: EXPERIMENTAL
Intervention: Child training group (CT)
Number of subjects: 97
Study 9103739 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined child and parent training group (CT + PT)
Number of subjects: 97
Study 9103739 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group (CON)
Number of subjects: 97
Study 8466094 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser acupuncture
Number of subjects: 0
Study 3003317 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicarbonate-containing oral rehydration solution
Number of subjects: 97
Study 3003317 — intervention group
Group type: COMPARATOR
Intervention: Citrate-containing oral rehydration solution
Number of subjects: 97
Study 31764959 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanabecestat 20 mg
Number of subjects: 2218
Study 31764959 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanabecestat 50 mg
Number of subjects: 2218
Study 31764959 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2218
Study 31152876 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylene blue in surfactant vehicle with 5 min irradiation
Number of subjects: 30
Study 31152876 — intervention group
Group type: COMPARATOR
Intervention: Aqueous methylene blue‐mediated PDT
Number of subjects: 30
Study 28367952 — intervention group
Group type: EXPERIMENTAL
Intervention: B-vitamin supplementation (2.5 mg/d folic acid, 50 mg/d vitamin B6, 1 mg/d vitamin B12)
Number of subjects: 10
Study 28367952 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 25682480 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine (400mg/day)
Number of subjects: 60
Study 25682480 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 25682480 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 60
Study 23692616 — intervention group
Group type: EXPERIMENTAL
Intervention: NIV (16 cmH2O IPS and 5 cmH2O PEEP) plus HOx (FiO2 = 0.4)
Number of subjects: 13
Study 23692616 — intervention group
Group type: COMPARATOR
Intervention: Sham NIV (7 cmH2O IPS and 5 cmH2O PEEP) plus HOx
Number of subjects: 13
Study 22014760 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding (BF)
Number of subjects: 57
Study 22014760 — intervention group
Group type: COMPARATOR
Intervention: Soother (Control)
Number of subjects: 57
Study 19852814 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 microgram of misoprostol
Number of subjects: 117
Study 19852814 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study 16500387 — intervention group
Group type: EXPERIMENTAL
Intervention: Transduodenal radial EUS of the biliary tree
Number of subjects: 95
Study 14980920 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampofol (lower-lipid emulsion of propofol)
Number of subjects: 63
Study 14980920 — intervention group
Group type: COMPARATOR
Intervention: Diprivan (standard propofol emulsion)
Number of subjects: 63
Study 14980920 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampofol
Number of subjects: 63
Study 14980920 — intervention group
Group type: COMPARATOR
Intervention: Diprivan
Number of subjects: 63
Study 11729795 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 0
Study 11729795 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 0
Study 9754894 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (enoxaparin) with or without TED stockings
Number of subjects: 78
Study 9754894 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 8132702 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg coumarin and cimetidine daily
Number of subjects: 40
Study 8132702 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g coumarin daily
Number of subjects: 40
Study 8132702 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g coumarin daily
Number of subjects: 40
Study 8132702 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 3043033 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefbuperazone (CBPZ) 4 g/day
Number of subjects: 32
Study 3043033 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefbuperazone (CBPZ) 2 g/day
Number of subjects: 32
Study 3043033 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefbuperazone (CBPZ)
Number of subjects: 32
Study 1473409 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral gentamicin and metronidazole for two days
Number of subjects: 16
Study 1473409 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined (oral + i.v.) gentamicin and metronidazole
Number of subjects: 16
Study 54578 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral disopyramide
Number of subjects: 0
Study 54578 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31013235 — intervention group
Group type: EXPERIMENTAL
Intervention: DARSI program (Developing Healthy and Egalitarian Adolescent Relationships)
Number of subjects: 191
Study 31013235 — intervention group
Group type: COMPARATOR
Intervention: Control groups (2 control groups)
Number of subjects: 191
Study 28122555 — intervention group
Group type: EXPERIMENTAL
Intervention: Deployment of trained community reproductive nurses (CORN) in health centres (arm 1)
Number of subjects: 282
Study 28122555 — intervention group
Group type: EXPERIMENTAL
Intervention: Deployment of trained community reproductive nurses (CORN) in community/health posts (arm 2)
Number of subjects: 282
Study 28122555 — intervention group
Group type: COMPARATOR
Intervention: Control villages without the intervention (arm 3)
Number of subjects: 282
Study 26047892 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmirtazapine 3.0 mg
Number of subjects: 419
Study 26047892 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmirtazapine 4.5 mg
Number of subjects: 419
Study 26047892 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 419
Study 26047892 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmirtazapine (both doses)
Number of subjects: 419
Study 26047892 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmirtazapine
Number of subjects: 419
Study 23583010 — intervention group
Group type: EXPERIMENTAL
Intervention: Zonisamide
Number of subjects: 41
Study 23583010 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 21451509 — intervention group
Group type: EXPERIMENTAL
Intervention: CCX354 100 mg single dose
Number of subjects: 0
Study 21451509 — intervention group
Group type: EXPERIMENTAL
Intervention: CCX354 300 mg single dose
Number of subjects: 0
Study 21451509 — intervention group
Group type: EXPERIMENTAL
Intervention: CCX354 1-300 mg/day oral doses
Number of subjects: 0
Study 21451509 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19944874 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Disease Self‐Management Program (CDSMP)
Number of subjects: 186
Study 16622646 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (600 mg/day during chemotherapy and 3 months after cessation)
Number of subjects: 30
Study 16622646 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vitamin E supplementation)
Number of subjects: 30
Study 15228804 — intervention group
Group type: EXPERIMENTAL
Intervention: robot training plus conventional therapy
Number of subjects: 56
Study 15228804 — intervention group
Group type: COMPARATOR
Intervention: conventional therapy
Number of subjects: 56
Study 11264915 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage therapy
Number of subjects: 24
Study 11264915 — intervention group
Group type: COMPARATOR
Intervention: Progressive muscle relaxation
Number of subjects: 24
Study 9886157 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon monoxide (3.9%) exposure at sea level
Number of subjects: 17
Study 9886157 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated high-altitude clean air exposure
Number of subjects: 17
Study 9886157 — intervention group
Group type: EXPERIMENTAL
Intervention: Sea-level carbon monoxide exposure
Number of subjects: 17
Study 9886157 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint exposure to carbon monoxide at simulated high altitude
Number of subjects: 17
Study 9886157 — intervention group
Group type: COMPARATOR
Intervention: Simulated high altitude
Number of subjects: 17
Study 8002849 — intervention group
Group type: EXPERIMENTAL
Intervention: Low cholesterol levels
Number of subjects: 0
Study 8002849 — intervention group
Group type: COMPARATOR
Intervention: Cholesterol-lowering strategies
Number of subjects: 0
Study 2927483 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 2927483 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (160 mg and 800 mg, given orally four times a day for 10 days, then 160 mg and 800 mg three times a week)
Number of subjects: 32
Study 2927483 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine and pyrimethamine (500 mg and 25 mg weekly)
Number of subjects: 32
Study 2927483 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic regimen (trimethoprim-sulfamethoxazole or sulfadoxine-pyrimethamine)
Number of subjects: 32
Study 30729418 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (LS screening)
Number of subjects: 194
Study 30729418 — intervention group
Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 194
Study 28369942 — intervention group
Group type: EXPERIMENTAL
Intervention: Operator knew fetal spine position (Group B)
Number of subjects: 58
Study 28369942 — intervention group
Group type: COMPARATOR
Intervention: Operator did not know fetal spine position (Group A)
Number of subjects: 58
Study 24689695 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-guided, basal-prandial insulin treatment protocol (NGP)
Number of subjects: 53
Study 24689695 — intervention group
Group type: COMPARATOR
Intervention: Physician-guided therapy (PGT)
Number of subjects: 53
Study 23375931 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower body positive pressure (LBPP) for 15 min
Number of subjects: 28
Study 23375931 — intervention group
Group type: COMPARATOR
Intervention: Control (antishock trousers deflated)
Number of subjects: 28
Study 21401358 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg daily for 18 months
Number of subjects: 93
Study 21401358 — intervention group
Group type: COMPARATOR
Intervention: Control group (no omeprazole)
Number of subjects: 93
Study 21401358 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole group
Number of subjects: 93
Study 21401358 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 93
Study 18481292 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG (Coronary Artery Bypass Grafting)
Number of subjects: 244
Study 18481292 — intervention group
Group type: COMPARATOR
Intervention: Nonsurgical cardiac comparison
Number of subjects: 244
Study 16571155 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g/d of trans-11-18:1 (tVA) and 3 g/d of trans-12-18:1 (t12)
Number of subjects: 0
Study 16571155 — intervention group
Group type: COMPARATOR
Intervention: Control oil
Number of subjects: 0
Study 12846896 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant erythropoietin (r‐EPO) at a single, weekly dose of 40,000 U for at least 8 weeks
Number of subjects: 13
Study 12846896 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant erythropoietin (r‐EPO)
Number of subjects: 13
Study 11232746 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (5-20 mg/day)
Number of subjects: 0
Study 11232746 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (5-20 mg/day)
Number of subjects: 0
Study 9506336 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol (200 mg/day)
Number of subjects: 41
Study 9506336 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (250 mg/day)
Number of subjects: 41
Study 7528126 — intervention group
Group type: EXPERIMENTAL
Intervention: New antiepileptic drugs in add-on trials
Number of subjects: 0
Study 7528126 — intervention group
Group type: COMPARATOR
Intervention: Placebo in add-on trials
Number of subjects: 0
Study 7528126 — intervention group
Group type: EXPERIMENTAL
Intervention: New antiepileptic drugs in monotherapy designs
Number of subjects: 0
Study 7528126 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic failure criteria
Number of subjects: 0
Study 3164788 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Number of subjects: 0
Study 30702538 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized opioid dosing protocol for VOE management
Number of subjects: 236
Study 30702538 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-based opioid dosing protocol for VOE management
Number of subjects: 236
Study 30702538 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized protocol
Number of subjects: 236
Study 30702538 — intervention group
Group type: COMPARATOR
Intervention: Usual ED strategy
Number of subjects: 236